| Literature DB >> 29357251 |
Xiaoming Wen1, Purong Zheng1, Yao Ma2, Yingye Ou1, Weixin Huang1, Shuo Li1, Shoujia Liu1, Xuan Zhang1, Ziyu Wang1, Qianli Zhang1, Wenming Cheng1, Ruwen Lin1, Hongzu Li1, Youyou Cai1, Chunyun Hu1, Ningbin Wu1, Long Wan1, Tingting Pan1, Jinlong Rao1, Xuelu Bei1, Weibin Wu1, Jian Jin1, Jie Yan1, Gang Liu2.
Abstract
Salutaxel (3) is a conjugate of docetaxel (7) and a muramyl dipeptide (MDP) analogue. Docetaxel (7) has been recognized as a highly active chemotherapeutic agent against various cancers. MDP and its analogues are powerful potentiators of the antitumor actions of various tumor-necrotizing agents. This article documents the discovery of compound 3 and presents pharmacological proof of its biological function in tumor-bearing mice. Drug candidate 3 was superior to compound 7 in its ability to prevent tumor growth and metastasis. Compound 3 suppressed myeloid-derived suppressor cell (MDSC) accumulation in the spleens of tumor-bearing mice and decreased various serum inflammatory cytokines levels. Furthermore, compound 3 antagonized the nucleotide-binding oligomerization domain-like receptor 1 (NOD1) signaling pathway both in vitro and in vivo.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29357251 DOI: 10.1021/acs.jmedchem.7b01407
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446